Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 9/20 | 0.32 |
| ▸ | HTR2A | P28223 | 8/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28861793 | 0.85 | TSHR (0.43) | ALDH1A1 | |
| SCHEMBL26779814 | 0.81 | TSHR (0.40) | ALDH1A1GRIA1OPRM1MPO | |
| SCHEMBL27608397 | 0.79 | OPRM1 (0.33) | OPRM1MPO | |
| SCHEMBL5282402 | 0.79 | GRIA1 (0.51) | ALDH1A1GRIK1GRIA1 | |
| SCHEMBL11705032 | 0.76 | GRIN1 (0.40) | — | |
| SCHEMBL1923337 | 0.75 | CYP1A2 (0.44) | ALDH1A1 | |
| SCHEMBL4372132 | 0.75 | CCR8 (0.32) | ALDH1A1 | |
| SCHEMBL4348692 | 0.74 | ADRA1D (0.37) | OPRM1MPO | |
| SCHEMBL26779812 | 0.74 | CDK4 (0.39) | ALDH1A1 | |
| SCHEMBL26779833 | 0.74 | CDK4 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4709417-A2 | POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20120046346-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011130624-A2 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011103137-A1 | CELL-BASED METHODS AND REAGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110150894-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011005765-A1 | BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005786-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005793-A1 | CELL-BASED BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2009155504-A9 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009155504-A2 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009149239-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, RNGTT, METTL16 | ALDH1A1 4724/4885GRIK1 4859/4885GRIA1 4764/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | ALDH1A1 2053/4885GRIK1 4808/4885GRIA1 4381/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | ALDH1A1 4705/4885GRIK1 4845/4885GRIA1 4670/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | ALDH1A1 3617/4885GRIK1 4839/4885GRIA1 4806/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | ALDH1A1 4565/4885GRIK1 4308/4885GRIA1 3431/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | ALDH1A1 4802/4885GRIK1 4013/4885GRIA1 3728/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | ALDH1A1 4843/4885GRIK1 4253/4885GRIA1 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.